Eisai is building a bespoke Cambridge research center with a $100M-plus plan to find new ways to tackle Alzheimer's
With a steady drumbeat of bad news set to the tempo of doom and gloom in the Alzheimer’s/dementia research world playing in the background, Eisai is creating its own $100 million-plus plan to start fresh and blaze some new research trails that go beyond tau and amyloid beta.
The Japanese company is building a 50,000-square-foot research home at the Alewife Research Center close to the heart of the humming Cambridge, MA biotech hub. Drawing on current staffers from their Andover site — which is being shut down — and adding some new skill sets, company execs plan to assemble a team of more than 80 scientists at the Eisai Center for Genetics Guided Dementia Discovery.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
